[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fR2HXXc5PNcHIpra9HiMAy50ttpy4nQunkhdLc84SRMI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":65,"rows":72},"University of Leipzig",[4],147,false,28,10,1054901,7,115,[14,17,19,22,25,27,29,32],{"name":15,"count":16},"Myocardial Infarction",6,{"name":18,"count":16},"Obesity",{"name":20,"count":21},"Atrial Fibrillation",5,{"name":23,"count":24},"Heart Failure",4,{"name":26,"count":24},"Coronary Artery Disease",{"name":28,"count":24},"Myelodysplastic Syndromes",{"name":30,"count":31},"Atrial Flutter",3,{"name":33,"count":31},"Impaired Glucose Tolerance",[35,40,45,50,55,60],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05833438","Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy","2025-11-16","VEN+AZA-5",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05384691","Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions","2026-07-31","Luspatercept",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06058442","The Pancreatic Enzymes After Gastrectomy Trial","2027-06","NORTASE®",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06656988","A Contrast Medium Sparing Strategy Using Automated CO2 Injection During PVI for Prevention of Major Adverse Kidney Events (MAKE)","2028-02","CO2",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT05551299","Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy","2028-04","Photosensitizer",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT06137378","European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]","2028-12","KEYTRUDA®",[66,67,68,69,70,71],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[73,97,118,142,160,193,215,238,266,284,311,329,347,370,408,426,452,470,495,523,548,566,592,617,642,669,687,712,735,760,783,809,836,854,880,907,925,950,977,1003,1030],{"intervention":59,"totalTrials":74,"cells":75},1,{"EARLY_PHASE1":76,"PHASE1":79,"PHASE2":81,"PHASE3":83,"PHASE4":85,"NA":95},{"trials":77,"activeCount":78},[],0,{"trials":80,"activeCount":78},[],{"trials":82,"activeCount":78},[],{"trials":84,"activeCount":78},[],{"trials":86,"activeCount":74,"soonestReadout":58},[87],{"nctId":56,"briefTitle":57,"status":88,"phases":89,"primaryCompletion":58,"completion":58,"start":90,"enrollment":91,"conditions":92,"interventions":94},"RECRUITING",[70],"2023-02-10",258,[93],"Hilar Cholangiocarcinoma",[59],{"trials":96,"activeCount":78},[],{"intervention":49,"totalTrials":74,"cells":98},{"EARLY_PHASE1":99,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":114,"NA":116},{"trials":100,"activeCount":78},[],{"trials":102,"activeCount":78},[],{"trials":104,"activeCount":78},[],{"trials":106,"activeCount":74,"soonestReadout":48},[107],{"nctId":46,"briefTitle":47,"status":88,"phases":108,"primaryCompletion":48,"completion":48,"start":109,"enrollment":110,"conditions":111,"interventions":113},[69],"2024-01-24",188,[112],"Gastrectomy",[49],{"trials":115,"activeCount":78},[],{"trials":117,"activeCount":78},[],{"intervention":54,"totalTrials":74,"cells":119},{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":126,"PHASE4":138,"NA":140},{"trials":121,"activeCount":78},[],{"trials":123,"activeCount":78},[],{"trials":125,"activeCount":78},[],{"trials":127,"activeCount":74,"soonestReadout":53},[128],{"nctId":51,"briefTitle":52,"status":88,"phases":129,"primaryCompletion":53,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":136},[69],"2029-02","2025-04-14",1960,[134,135],"Peripheral Vascular Diseases","Kidney Diseases",[54,137],"Iodinated Contrast Media",{"trials":139,"activeCount":78},[],{"trials":141,"activeCount":78},[],{"intervention":137,"totalTrials":74,"cells":143},{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":150,"PHASE4":156,"NA":158},{"trials":145,"activeCount":78},[],{"trials":147,"activeCount":78},[],{"trials":149,"activeCount":78},[],{"trials":151,"activeCount":74,"soonestReadout":53},[152],{"nctId":51,"briefTitle":52,"status":88,"phases":153,"primaryCompletion":53,"completion":130,"start":131,"enrollment":132,"conditions":154,"interventions":155},[69],[134,135],[54,137],{"trials":157,"activeCount":78},[],{"trials":159,"activeCount":78},[],{"intervention":64,"totalTrials":74,"cells":161},{"EARLY_PHASE1":162,"PHASE1":164,"PHASE2":166,"PHASE3":187,"PHASE4":189,"NA":191},{"trials":163,"activeCount":78},[],{"trials":165,"activeCount":78},[],{"trials":167,"activeCount":74,"soonestReadout":63},[168],{"nctId":61,"briefTitle":62,"status":88,"phases":169,"primaryCompletion":63,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":186},[68],"2030-12","2024-04-17",140,[174,175,176,177,178,179,180,181,182,183,184,185],"Squamous Cell Carcinoma of Head and Neck","Hypopharyngeal Squamous Cell Carcinoma","Laryngeal Squamous Cell Carcinoma Stage III","Laryngeal Squamous Cell Carcinoma Stage IV","Squamous Cell Carcinoma of Larynx","Squamous Cell Carcinoma of the Larynx","Squamous Cell Carcinoma of the Larynx Stage III","Squamous Cell Carcinoma of the Larynx Stage IV","Laryngeal Squamous Cell Carcinoma","Laryngectomy; Status","Laryngeal Cancer","Laryngeal Neoplasms",[64],{"trials":188,"activeCount":78},[],{"trials":190,"activeCount":78},[],{"trials":192,"activeCount":78},[],{"intervention":44,"totalTrials":74,"cells":194},{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":209,"PHASE4":211,"NA":213},{"trials":196,"activeCount":78},[],{"trials":198,"activeCount":78},[],{"trials":200,"activeCount":74,"soonestReadout":43},[201],{"nctId":41,"briefTitle":42,"status":88,"phases":202,"primaryCompletion":43,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":208},[68],"2027-07-31","2022-09-27",213,[28,207],"Anemia",[44],{"trials":210,"activeCount":78},[],{"trials":212,"activeCount":78},[],{"trials":214,"activeCount":78},[],{"intervention":39,"totalTrials":74,"cells":216},{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":232,"PHASE4":234,"NA":236},{"trials":218,"activeCount":78},[],{"trials":220,"activeCount":78},[],{"trials":222,"activeCount":74,"soonestReadout":38},[223],{"nctId":36,"briefTitle":37,"status":224,"phases":225,"primaryCompletion":38,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":231},"ACTIVE_NOT_RECRUITING",[68],"2026-05","2023-05-17",45,[230],"Acute Myeloid Leukemia (AML)",[39],{"trials":233,"activeCount":78},[],{"trials":235,"activeCount":78},[],{"trials":237,"activeCount":78},[],{"intervention":239,"totalTrials":74,"cells":240},"niaspan",{"EARLY_PHASE1":241,"PHASE1":243,"PHASE2":245,"PHASE3":247,"PHASE4":249,"NA":264},{"trials":242,"activeCount":78},[],{"trials":244,"activeCount":78},[],{"trials":246,"activeCount":78},[],{"trials":248,"activeCount":78},[],{"trials":250,"activeCount":78},[251],{"nctId":252,"briefTitle":253,"status":254,"phases":255,"primaryCompletion":256,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":262},"NCT00298909","Exercise Versus Niacin in Patients With Coronary Artery Disease (CAD) and Low High-Density Lipoproteins (HDL)","COMPLETED",[70],"2009-06","2006-03",48,[260,261],"Coronary Disease","Hypolipoproteinemia",[239,263],"niacin",{"trials":265,"activeCount":78},[],{"intervention":263,"totalTrials":74,"cells":267},{"EARLY_PHASE1":268,"PHASE1":270,"PHASE2":272,"PHASE3":274,"PHASE4":276,"NA":282},{"trials":269,"activeCount":78},[],{"trials":271,"activeCount":78},[],{"trials":273,"activeCount":78},[],{"trials":275,"activeCount":78},[],{"trials":277,"activeCount":78},[278],{"nctId":252,"briefTitle":253,"status":254,"phases":279,"primaryCompletion":256,"completion":256,"start":257,"enrollment":258,"conditions":280,"interventions":281},[70],[260,261],[239,263],{"trials":283,"activeCount":78},[],{"intervention":285,"totalTrials":74,"cells":286},"pioglitazone",{"EARLY_PHASE1":287,"PHASE1":289,"PHASE2":291,"PHASE3":293,"PHASE4":295,"NA":309},{"trials":288,"activeCount":78},[],{"trials":290,"activeCount":78},[],{"trials":292,"activeCount":78},[],{"trials":294,"activeCount":78},[],{"trials":296,"activeCount":78},[297],{"nctId":298,"briefTitle":299,"status":300,"phases":301,"completion":302,"enrollment":303,"conditions":304,"interventions":306},"NCT00306826","Pioglitazone in Impaired Glucose Tolerance","WITHDRAWN",[70],"2009-05",120,[305],"Glucose Metabolism Disorders",[285,307,308],"simvastatin","pioglitazone + simvastatin",{"trials":310,"activeCount":78},[],{"intervention":307,"totalTrials":74,"cells":312},{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":319,"PHASE4":321,"NA":327},{"trials":314,"activeCount":78},[],{"trials":316,"activeCount":78},[],{"trials":318,"activeCount":78},[],{"trials":320,"activeCount":78},[],{"trials":322,"activeCount":78},[323],{"nctId":298,"briefTitle":299,"status":300,"phases":324,"completion":302,"enrollment":303,"conditions":325,"interventions":326},[70],[305],[285,307,308],{"trials":328,"activeCount":78},[],{"intervention":308,"totalTrials":74,"cells":330},{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":335,"PHASE3":337,"PHASE4":339,"NA":345},{"trials":332,"activeCount":78},[],{"trials":334,"activeCount":78},[],{"trials":336,"activeCount":78},[],{"trials":338,"activeCount":78},[],{"trials":340,"activeCount":78},[341],{"nctId":298,"briefTitle":299,"status":300,"phases":342,"completion":302,"enrollment":303,"conditions":343,"interventions":344},[70],[305],[285,307,308],{"trials":346,"activeCount":78},[],{"intervention":348,"totalTrials":74,"cells":349},"rosiglitazone",{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":356,"PHASE4":358,"NA":368},{"trials":351,"activeCount":78},[],{"trials":353,"activeCount":78},[],{"trials":355,"activeCount":78},[],{"trials":357,"activeCount":78},[],{"trials":359,"activeCount":78},[360],{"nctId":361,"briefTitle":362,"status":254,"phases":363,"primaryCompletion":364,"completion":364,"start":365,"enrollment":228,"conditions":366,"interventions":367},"NCT00675740","Physical Exercise Versus Rosiglitazone in CAD and Prediabetes",[70],"2007-02","2004-01",[33],[348],{"trials":369,"activeCount":78},[],{"intervention":371,"totalTrials":372,"cells":373},"Cytarabine",2,{"EARLY_PHASE1":374,"PHASE1":376,"PHASE2":378,"PHASE3":380,"PHASE4":404,"NA":406},{"trials":375,"activeCount":78},[],{"trials":377,"activeCount":78},[],{"trials":379,"activeCount":78},[],{"trials":381,"activeCount":78},[382,394],{"nctId":383,"briefTitle":384,"status":385,"phases":386,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":393},"NCT01414231","Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML\u003C60a","UNKNOWN",[69],"2013-12","2014-07","2002-04",850,[392],"Acute Myeloid Leukaemia",[371],{"nctId":395,"briefTitle":396,"status":254,"phases":397,"primaryCompletion":398,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":402},"NCT01497002","Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a",[69],"2018-07-18","2005-04",1222,[392],[371,403],"human stem cells",{"trials":405,"activeCount":78},[],{"trials":407,"activeCount":78},[],{"intervention":403,"totalTrials":74,"cells":409},{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":422,"NA":424},{"trials":411,"activeCount":78},[],{"trials":413,"activeCount":78},[],{"trials":415,"activeCount":78},[],{"trials":417,"activeCount":78},[418],{"nctId":395,"briefTitle":396,"status":254,"phases":419,"primaryCompletion":398,"completion":398,"start":399,"enrollment":400,"conditions":420,"interventions":421},[69],[392],[371,403],{"trials":423,"activeCount":78},[],{"trials":425,"activeCount":78},[],{"intervention":427,"totalTrials":74,"cells":428},"abciximab intracoronary",{"EARLY_PHASE1":429,"PHASE1":431,"PHASE2":433,"PHASE3":435,"PHASE4":448,"NA":450},{"trials":430,"activeCount":78},[],{"trials":432,"activeCount":78},[],{"trials":434,"activeCount":78},[],{"trials":436,"activeCount":78},[437],{"nctId":438,"briefTitle":439,"status":254,"phases":440,"primaryCompletion":441,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":446},"NCT00712101","Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction",[69],"2011-04","2008-07",1912,[445],"ST-elevation Myocardial Infarction",[427,447],"abciximab intravenously",{"trials":449,"activeCount":78},[],{"trials":451,"activeCount":78},[],{"intervention":447,"totalTrials":74,"cells":453},{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":460,"PHASE4":466,"NA":468},{"trials":455,"activeCount":78},[],{"trials":457,"activeCount":78},[],{"trials":459,"activeCount":78},[],{"trials":461,"activeCount":78},[462],{"nctId":438,"briefTitle":439,"status":254,"phases":463,"primaryCompletion":441,"completion":441,"start":442,"enrollment":443,"conditions":464,"interventions":465},[69],[445],[427,447],{"trials":467,"activeCount":78},[],{"trials":469,"activeCount":78},[],{"intervention":471,"totalTrials":74,"cells":472},"Acetylcystein",{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":479,"PHASE4":491,"NA":493},{"trials":474,"activeCount":78},[],{"trials":476,"activeCount":78},[],{"trials":478,"activeCount":78},[],{"trials":480,"activeCount":78},[481],{"nctId":482,"briefTitle":483,"status":254,"phases":484,"primaryCompletion":485,"completion":486,"start":487,"enrollment":488,"conditions":489,"interventions":490},"NCT00463749","Myocardial Salvage and Contrast Dye Induced Nephropathy Reduction by N-Acetylcystein",[69],"2008-02","2008-06","2006-12",251,[15],[471],{"trials":492,"activeCount":78},[],{"trials":494,"activeCount":78},[],{"intervention":496,"totalTrials":74,"cells":497},"Amiodarone",{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":519,"NA":521},{"trials":499,"activeCount":78},[],{"trials":501,"activeCount":78},[],{"trials":503,"activeCount":78},[],{"trials":505,"activeCount":78},[506],{"nctId":507,"briefTitle":508,"status":254,"phases":509,"primaryCompletion":510,"completion":511,"start":512,"enrollment":513,"conditions":514,"interventions":518},"NCT02924285","Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease",[69],"2020-12-30","2021-03-04","2017-11-01",80,[515,516,517],"Heart Diseases","Cardiomyopathies","Ventricular Premature Complexes",[496],{"trials":520,"activeCount":78},[],{"trials":522,"activeCount":78},[],{"intervention":524,"totalTrials":74,"cells":525},"Abciximab i.v.",{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":532,"PHASE4":544,"NA":546},{"trials":527,"activeCount":78},[],{"trials":529,"activeCount":78},[],{"trials":531,"activeCount":78},[],{"trials":533,"activeCount":78},[534],{"nctId":535,"briefTitle":536,"status":254,"phases":537,"primaryCompletion":538,"completion":485,"start":539,"enrollment":540,"conditions":541,"interventions":542},"NCT00299377","Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI",[68,69],"2007-11","2006-01",150,[15],[524,543],"Abciximab i.c.",{"trials":545,"activeCount":78},[],{"trials":547,"activeCount":78},[],{"intervention":543,"totalTrials":74,"cells":549},{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":556,"PHASE4":562,"NA":564},{"trials":551,"activeCount":78},[],{"trials":553,"activeCount":78},[],{"trials":555,"activeCount":78},[],{"trials":557,"activeCount":78},[558],{"nctId":535,"briefTitle":536,"status":254,"phases":559,"primaryCompletion":538,"completion":485,"start":539,"enrollment":540,"conditions":560,"interventions":561},[68,69],[15],[524,543],{"trials":563,"activeCount":78},[],{"trials":565,"activeCount":78},[],{"intervention":567,"totalTrials":74,"cells":568},"fluvastatin",{"EARLY_PHASE1":569,"PHASE1":571,"PHASE2":573,"PHASE3":586,"PHASE4":588,"NA":590},{"trials":570,"activeCount":78},[],{"trials":572,"activeCount":78},[],{"trials":574,"activeCount":78},[575],{"nctId":576,"briefTitle":577,"status":385,"phases":578,"primaryCompletion":579,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":585},"NCT00176410","Statin Therapy in Asymptomatic Aortic Stenosis",[68],"2009-09","2009-12","2003-01",100,[584],"Aortic Valve Stenosis",[567],{"trials":587,"activeCount":78},[],{"trials":589,"activeCount":78},[],{"trials":591,"activeCount":78},[],{"intervention":593,"totalTrials":74,"cells":594},"Cabozantinib",{"EARLY_PHASE1":595,"PHASE1":597,"PHASE2":599,"PHASE3":611,"PHASE4":613,"NA":615},{"trials":596,"activeCount":78},[],{"trials":598,"activeCount":78},[],{"trials":600,"activeCount":78},[601],{"nctId":602,"briefTitle":603,"status":254,"phases":604,"primaryCompletion":605,"completion":605,"start":606,"enrollment":607,"conditions":608,"interventions":610},"NCT04767906","Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors",[68],"2024-07-19","2021-12-14",16,[609],"Hepatocellular Carcinoma",[593],{"trials":612,"activeCount":78},[],{"trials":614,"activeCount":78},[],{"trials":616,"activeCount":78},[],{"intervention":618,"totalTrials":74,"cells":619},"Pembrolizumab 25 MG\u002F1 ML Intravenous Solution [KEYTRUDA]",{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":624,"PHASE3":636,"PHASE4":638,"NA":640},{"trials":621,"activeCount":78},[],{"trials":623,"activeCount":78},[],{"trials":625,"activeCount":78},[626],{"nctId":627,"briefTitle":628,"status":254,"phases":629,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":633,"interventions":635},"NCT03480672","Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma",[68],"2025-01-30","2018-08-06",211,[634],"HNSCC",[618],{"trials":637,"activeCount":78},[],{"trials":639,"activeCount":78},[],{"trials":641,"activeCount":78},[],{"intervention":643,"totalTrials":74,"cells":644},"Imatinib",{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":663,"PHASE4":665,"NA":667},{"trials":646,"activeCount":78},[],{"trials":648,"activeCount":78},[],{"trials":650,"activeCount":78},[651],{"nctId":652,"briefTitle":653,"status":254,"phases":654,"primaryCompletion":655,"completion":656,"start":657,"enrollment":658,"conditions":659,"interventions":661},"NCT02480608","Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)",[67,68],"2011-08","2013-05","2004-04",113,[660],"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",[643,662],"Hydroxyurea",{"trials":664,"activeCount":78},[],{"trials":666,"activeCount":78},[],{"trials":668,"activeCount":78},[],{"intervention":662,"totalTrials":74,"cells":670},{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":681,"PHASE4":683,"NA":685},{"trials":672,"activeCount":78},[],{"trials":674,"activeCount":78},[],{"trials":676,"activeCount":78},[677],{"nctId":652,"briefTitle":653,"status":254,"phases":678,"primaryCompletion":655,"completion":656,"start":657,"enrollment":658,"conditions":679,"interventions":680},[67,68],[660],[643,662],{"trials":682,"activeCount":78},[],{"trials":684,"activeCount":78},[],{"trials":686,"activeCount":78},[],{"intervention":688,"totalTrials":74,"cells":689},"Lenalidomide, Bendamustine, Prednisone",{"EARLY_PHASE1":690,"PHASE1":692,"PHASE2":694,"PHASE3":706,"PHASE4":708,"NA":710},{"trials":691,"activeCount":78},[],{"trials":693,"activeCount":78},[],{"trials":695,"activeCount":78},[696],{"nctId":697,"briefTitle":698,"status":385,"phases":699,"primaryCompletion":700,"completion":701,"start":579,"enrollment":702,"conditions":703,"interventions":705},"NCT01002703","Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma",[67,68],"2012-10","2014-10",50,[704],"Multiple Myeloma",[688],{"trials":707,"activeCount":78},[],{"trials":709,"activeCount":78},[],{"trials":711,"activeCount":78},[],{"intervention":713,"totalTrials":74,"cells":714},"rosuvastatin",{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":719,"PHASE3":729,"PHASE4":731,"NA":733},{"trials":716,"activeCount":78},[],{"trials":718,"activeCount":78},[],{"trials":720,"activeCount":78},[721],{"nctId":722,"briefTitle":723,"status":254,"phases":724,"completion":487,"start":725,"enrollment":726,"conditions":727,"interventions":728},"NCT00176332","Impact of Rosuvastatin on Endothelial Function and Inflammation in Patients With Chronic Heart Failure",[68],"2004-03",40,[23],[713],{"trials":730,"activeCount":78},[],{"trials":732,"activeCount":78},[],{"trials":734,"activeCount":78},[],{"intervention":736,"totalTrials":74,"cells":737},"CA-4948",{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":754,"PHASE4":756,"NA":758},{"trials":739,"activeCount":78},[],{"trials":741,"activeCount":78},[],{"trials":743,"activeCount":78},[744],{"nctId":745,"briefTitle":746,"status":747,"phases":748,"primaryCompletion":749,"completion":749,"start":750,"enrollment":751,"conditions":752,"interventions":753},"NCT05178342","Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948","TERMINATED",[68],"2024-07-31","2022-01-01",38,[28,207],[736],{"trials":755,"activeCount":78},[],{"trials":757,"activeCount":78},[],{"trials":759,"activeCount":78},[],{"intervention":761,"totalTrials":74,"cells":762},"Canakinumab",{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":777,"PHASE4":779,"NA":781},{"trials":764,"activeCount":78},[],{"trials":766,"activeCount":78},[],{"trials":768,"activeCount":78},[769],{"nctId":770,"briefTitle":771,"status":747,"phases":772,"primaryCompletion":773,"completion":773,"start":774,"enrollment":9,"conditions":775,"interventions":776},"NCT05237713","Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients",[68],"2024-02-29","2022-04-26",[207,28],[761],{"trials":778,"activeCount":78},[],{"trials":780,"activeCount":78},[],{"trials":782,"activeCount":78},[],{"intervention":784,"totalTrials":74,"cells":785},"Ranibizumab",{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":803,"PHASE4":805,"NA":807},{"trials":787,"activeCount":78},[],{"trials":789,"activeCount":78},[],{"trials":791,"activeCount":78},[792],{"nctId":793,"briefTitle":794,"status":254,"phases":795,"primaryCompletion":796,"completion":797,"start":798,"enrollment":799,"conditions":800,"interventions":802},"NCT01968239","Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT",[68],"2016-06-17","2016-12-20","2013-10",27,[801],"Branch Retinal Vein Occlusion",[784],{"trials":804,"activeCount":78},[],{"trials":806,"activeCount":78},[],{"trials":808,"activeCount":78},[],{"intervention":810,"totalTrials":74,"cells":811},"Pevonedistat",{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":816,"PHASE3":830,"PHASE4":832,"NA":834},{"trials":813,"activeCount":78},[],{"trials":815,"activeCount":78},[],{"trials":817,"activeCount":78},[818],{"nctId":819,"briefTitle":820,"status":254,"phases":821,"primaryCompletion":822,"completion":822,"start":823,"enrollment":824,"conditions":825,"interventions":828},"NCT04712942","Treatment of MDS\u002FAML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat",[68],"2023-01-31","2021-01-01",14,[826,28,827],"Acute Myeloid Leukemia in Remission","Minimal Residual Disease",[810,829],"Azacitidine",{"trials":831,"activeCount":78},[],{"trials":833,"activeCount":78},[],{"trials":835,"activeCount":78},[],{"intervention":829,"totalTrials":74,"cells":837},{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":848,"PHASE4":850,"NA":852},{"trials":839,"activeCount":78},[],{"trials":841,"activeCount":78},[],{"trials":843,"activeCount":78},[844],{"nctId":819,"briefTitle":820,"status":254,"phases":845,"primaryCompletion":822,"completion":822,"start":823,"enrollment":824,"conditions":846,"interventions":847},[68],[826,28,827],[810,829],{"trials":849,"activeCount":78},[],{"trials":851,"activeCount":78},[],{"trials":853,"activeCount":78},[],{"intervention":855,"totalTrials":74,"cells":856},"Paromomycin Sulfate Powder",{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":863,"PHASE4":865,"NA":867},{"trials":858,"activeCount":78},[],{"trials":860,"activeCount":78},[],{"trials":862,"activeCount":78},[],{"trials":864,"activeCount":78},[],{"trials":866,"activeCount":78},[],{"trials":868,"activeCount":78},[869],{"nctId":870,"briefTitle":871,"status":385,"phases":872,"primaryCompletion":873,"completion":874,"start":875,"enrollment":582,"conditions":876,"interventions":879},"NCT03759886","Oral Antibiotic Prophylaxis in Colorectal Surgery",[],"2020-05-01","2020-12-01","2018-12-17",[877,878],"Surgical Site Infection","Anastomotic Leak",[855],{"intervention":881,"totalTrials":74,"cells":882},"UDCA",{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":889,"PHASE4":891,"NA":893},{"trials":884,"activeCount":78},[],{"trials":886,"activeCount":78},[],{"trials":888,"activeCount":78},[],{"trials":890,"activeCount":78},[],{"trials":892,"activeCount":78},[],{"trials":894,"activeCount":78},[895],{"nctId":896,"briefTitle":897,"status":385,"phases":898,"primaryCompletion":899,"completion":899,"start":900,"enrollment":901,"conditions":902,"interventions":905},"NCT04076527","Prospective, Multicenter Cohort Study on Primary Biliary Cholangitis",[],"2024-03","2019-09-19",1200,[903,904],"PBC","Primary Biliary Cholangitis",[881,906],"Ocaliva",{"intervention":906,"totalTrials":74,"cells":908},{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":913,"PHASE3":915,"PHASE4":917,"NA":919},{"trials":910,"activeCount":78},[],{"trials":912,"activeCount":78},[],{"trials":914,"activeCount":78},[],{"trials":916,"activeCount":78},[],{"trials":918,"activeCount":78},[],{"trials":920,"activeCount":78},[921],{"nctId":896,"briefTitle":897,"status":385,"phases":922,"primaryCompletion":899,"completion":899,"start":900,"enrollment":901,"conditions":923,"interventions":924},[],[903,904],[881,906],{"intervention":926,"totalTrials":74,"cells":927},"G-CSF",{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":932,"PHASE3":934,"PHASE4":936,"NA":938},{"trials":929,"activeCount":78},[],{"trials":931,"activeCount":78},[],{"trials":933,"activeCount":78},[],{"trials":935,"activeCount":78},[],{"trials":937,"activeCount":78},[],{"trials":939,"activeCount":78},[940],{"nctId":941,"briefTitle":942,"status":254,"phases":943,"primaryCompletion":944,"completion":944,"start":945,"enrollment":946,"conditions":947,"interventions":949},"NCT02669680","Granulocyte Colony Stimulating Factor (G-CSF) to Treat Acute-on-chronic Liver Failure",[71],"2020-03","2016-02",176,[948],"Acute-On-Chronic Liver Failure",[926],{"intervention":951,"totalTrials":74,"cells":952},"PNPLA3",{"EARLY_PHASE1":953,"PHASE1":955,"PHASE2":957,"PHASE3":959,"PHASE4":961,"NA":963},{"trials":954,"activeCount":78},[],{"trials":956,"activeCount":78},[],{"trials":958,"activeCount":78},[],{"trials":960,"activeCount":78},[],{"trials":962,"activeCount":78},[],{"trials":964,"activeCount":78},[965],{"nctId":966,"briefTitle":967,"status":254,"phases":968,"primaryCompletion":969,"completion":970,"start":971,"enrollment":972,"conditions":973,"interventions":976},"NCT02779946","Non-invasive Liver Screening for Risk Assessment for Coronary Heart Disease",[],"2017-03","2017-06","2015-10",216,[260,974,975],"Non-alcoholic Fatty Liver Disease","Elasticity Imaging Techniques",[951],{"intervention":978,"totalTrials":74,"cells":979},"Sacubitril-Valsartan",{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":986,"PHASE4":988,"NA":990},{"trials":981,"activeCount":78},[],{"trials":983,"activeCount":78},[],{"trials":985,"activeCount":78},[],{"trials":987,"activeCount":78},[],{"trials":989,"activeCount":78},[],{"trials":991,"activeCount":78},[992],{"nctId":993,"briefTitle":994,"status":254,"phases":995,"primaryCompletion":996,"completion":997,"start":998,"enrollment":999,"conditions":1000,"interventions":1002},"NCT04498780","Hemodynamic Effects of ARNI on Noninvasive Pressure-volume Analysis in Patients With Chronic Heart Failure",[],"2025-12-31","2026-04-08","2020-07-21",117,[1001],"Heart Failure With Reduced Ejection Fraction",[978],{"intervention":1004,"totalTrials":74,"cells":1005},"Anti-VEGF",{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1010,"PHASE3":1012,"PHASE4":1014,"NA":1016},{"trials":1007,"activeCount":78},[],{"trials":1009,"activeCount":78},[],{"trials":1011,"activeCount":78},[],{"trials":1013,"activeCount":78},[],{"trials":1015,"activeCount":78},[],{"trials":1017,"activeCount":78},[1018],{"nctId":1019,"briefTitle":1020,"status":385,"phases":1021,"primaryCompletion":1022,"completion":1023,"start":1024,"enrollment":582,"conditions":1025,"interventions":1029},"NCT03762226","Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study",[],"2021-06-30","2021-12-31","2018-09-01",[1026,1027,1028],"Diabetic Macular Edema","Macular Edema","Retinal Vein Occlusion",[1004],{"intervention":1031,"totalTrials":74,"cells":1032},"Elidel",{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1037,"PHASE3":1039,"PHASE4":1041,"NA":1043},{"trials":1034,"activeCount":78},[],{"trials":1036,"activeCount":78},[],{"trials":1038,"activeCount":78},[],{"trials":1040,"activeCount":78},[],{"trials":1042,"activeCount":78},[],{"trials":1044,"activeCount":78},[1045],{"nctId":1046,"briefTitle":1047,"status":300,"phases":1048,"start":1049,"enrollment":78,"conditions":1050,"interventions":1053},"NCT00222183","Cutaneous Lupus Erythematosus and Elidel",[71],"2003-06",[1051,1052],"Lupus Erythematosus, Cutaneous","Lupus Erythematosus, Discoid",[1031]]